Sold as Isovue-M 200, Isovue-300, Isovue-370, Isovue-M 300, Isovue-128 and 3 more. Every FDA application for this active ingredient: 3 branded and 12 generic.
As of Nov 15, 2026, FDA lists 15 applications for Iopamidol (sold as Isovue-M 200, Isovue-300, Isovue-370 and others), first approved Dec 31, 1985, with 11 new uses approved and 0 published complete response letters.
| Study | Phase | Status | Posted |
|---|---|---|---|
| Rectus Sheath Block With Liposomal Bupivacaine Versus Thoracic Epidural Analgesia for Pain Control Following PancreatoduodenectomyDuodenal Neoplasm, Pancreatic Neoplasm · Masonic Cancer Center, University of Minnesota | Phase 2 | Recruiting | May 13, 2024 |
| Dec 31, 1985 | Isovue-M 200, Isovue-300NDA 18735 · New molecular entity | Bracco | 55 | Marketed |
| Oct 12, 1994 | Isovue-200, Isovue-250NDA 20327 · New formulation or manufacturer | Bracco | 14 | Marketed |
| Nov 6, 1996 | IopamidolANDA 74629 | Baxter Hlthcare | 5 | Discontinued |
| Apr 2, 1997 | Iopamidol-250, Iopamidol-300ANDA 74679 | Fresenius Kabi USA | 4 | Discontinued |
| Apr 3, 1997 | Iopamidol-300 In Plastic ContainerANDA 74637 | Hospira | 1 | Discontinued |
| Apr 30, 1997 | Iopamidol-300ANDA 74638 | Abbvie | 0 | Discontinued |
| Dec 30, 1997 | Iopamidol-200 In Plastic Container, Iopamidol-250 In Plastic ContainerANDA 74636 | Hospira | 1 | Discontinued |
| Dec 30, 1997 | Iopamidol-200, Iopamidol-250ANDA 74898 | Hospira | 1 | Discontinued |
| Feb 24, 1998 | Iopamidol-250, Iopamidol-300ANDA 75005 | Hospira | 0 | Discontinued |
| Jul 28, 2000 | Iopamidol-200, Iopamidol-250ANDA 74881 | Cook Imaging | 2 | Discontinued |
| Jun 18, 2010 | Scanlux-300, Scanlux-370ANDA 90394 | Sanochemia Corp USA | 0 | Discontinued |
| Feb 27, 2023 | IopamidolANDA 215382 | Hainan Poly | 0 | Marketed |
| Sep 27, 2023 | IopamidolANDA 217134 | Hainan Poly | 1 | Marketed |
| Oct 9, 2026 | Isovue ReadiNDA 220583 · New formulation or manufacturer | Bracco | 0 | Marketed |
| — | IopamidolANDA 74734 | Hospira | 0 | Discontinued |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA